Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 19, 2007

Thermo Fisher Scientific Opens RNAi Services Lab

  • Thermo Fisher Scientific opened an RNAi Discovery and Therapeutic Services laboratory. The facility offers advanced RNAi screening and analysis services as well as development of new therapeutic technologies involving RNAi. The lab is based at its RNAi research and production center in Lafayette, CO.

    "Our core expertise in RNAi biology and therapeutic technology development, high-throughput screening, RNA chemistry, and drug discovery research combined with our unique portfolio of bioreagents, instrument systems, and robotics, enables us to perform highly advanced contract services in-house," according to Marc N. Casper, executive vp of Thermo Fisher Scientific.

    The RNAi contract services provides critical drug discovery activities and supplemental resources and expertise for overburdened labs already using RNAi technology. Services range from a single screen to multicomponent projects and include RNAi-based high-throughput screening and hit validation, high-content screening, miRNA expression profiling and analysis, as well as lab automation and integration. Therapeutic discovery and technology development is also available for clients pursuing RNAi-based therapeutics.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »